Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 November 2023

EMA’s safety committee, PRAC, has recommended new measures for medicines containing pseudoephedrine to minimise the risks of posterior reversible encephalopathy syndrome (PRES)…, Agenda Agenda of the PRAC meeting 27-30 November 2023DraftFirst published: 27/11/2023Reference Number: EMA/PRAC/477373/2023…, PRAC statistics: December 2023, Glossary:Safety signal assessments. A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between a medicine…, Ongoing referralsProcedureStatusUpdateHydroxyprogesterone-containing medicinal products – Article-31 referralUnder evaluationPRAC continued its assessment

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-27-30-november-2023https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-27-30-november-2023
Retrieved on: 
Monday, December 18, 2023
Information
Tags: 
Medicine, Vomiting, Brain, Liraglutide, European Commission, Pseudoephedrine, Semaglutide, RCVS, PRES, Headache, Dulaglutide, Allergy, Kidney disease, State, EMA, Civil service commission, Signal, Patient, DSM-IV codes, Exenatide, Association, RMP, Vaccine, CHMP, Reversible cerebral vasoconstriction syndrome, Marketing, Data, COVID-19, Seizure, Diagnosis, Communication, Direct, Health care, Review, Failure, PRAC, Confusion, Public, Pharmaceutical industry, Hospital, Dietary supplement, Medical device, Safety
Geotags: 
EU
Summary
Key Points: 


EMA’s safety committee, PRAC, has recommended new measures for medicines containing pseudoephedrine to minimise the risks of posterior reversible encephalopathy syndrome (PRES)…, Agenda Agenda of the PRAC meeting 27-30 November 2023DraftFirst published: 27/11/2023Reference Number: EMA/PRAC/477373/2023…, PRAC statistics: December 2023, Glossary:Safety signal assessments. A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between a medicine…, Ongoing referralsProcedureStatusUpdateHydroxyprogesterone-containing medicinal products – Article-31 referralUnder evaluationPRAC continued its assessment

Copyright: 
2023 European Medicines Agency. All Rights Reserved.